What is direct-to-consumer genetic testing? DTC refers to genetic tests marketed and sold directly to individuals, bypassing the primary care provider in the traditional healthcare system [2] . DTC genetic testing services advertise widely -in magazines, television, and the Internet. The consumer contacts the company and receives a kit with which to return a DNA sample (usually saliva or a buccal swab) for the desired test. The variety of genetic tests that companies offer range from novelty type information such as ancestry; to tests to determine specific risk, such as BRCA1/2 testing; to tests that predict the sensitivity and efficacy of specific drugs (as discussed in the article by Evans in this issue); to tests of indeterminate clinical utility, such as those that determine a relative risk for developing Alzheimer disease [3] . For a fee (in a recent government report DTC genetic susceptibility tests ranged from US$ 299 to 999), a company will perform the selected tests and provide the results directly to the consumer. Some companies offer genetic counselors or other healthcare professionals by phone to discuss the test results.
Proponents view DTC genetic testing as a further step in self-empowerment, permitting easier access to one's genetic information. In terms of bioethical principles, DTC genetic testing offers strong potential benefit with regards to individual autonomy. However, autonomy is not limitless -it can be curbed if 'there is danger of harms or risk to individuals or groups' [4] . In this regard, one potential harm associated with DTC genetic testing would be a consumer making health-related choices based on a falsely reassuring test result. For example, an individual with a family history of colon cancer may have an interest in determining if they carry an increased genetic risk for developing colon cancer, and this interest may lead them to order a health susceptibility test for colon cancer. If the health susceptibility test reports a normal or below average risk for colon cancer, the individual may decide that, based on this test, they will forgo screening despite their family history. This would be faulty reasoning, though, as to date family history is still the most consistent risk factor for common chronic conditions and its presence increases the risk of disease regardless of genetic variants [5] . In the clinical setting, these critical nuances would be explained by a genetics healthcare professional, but with DTC the 'customer' is literally on their own to figure this out.
Several genetics professional societies [6, 7] have issued statements highlighting these and other potential harms associated with DTC genetic testing. In these statements a common theme is the lack of adequate communication between the company and the consumer on the meaning and limitations of the test results. This is echoed in the recent report of the United States Government Accountability Office (GAO) [5] , which found that the reporting of DTC genetic test results did not meet the consumer need for clarity. In the report, the comparison of test results among companies was confusing, the methods used to derive the results were unclear, and the counseling provided in follow-up of the results was nonspecific. When the consumers in the GAO study asked what more they could do to understand their results, many companies recommended the consumers take the results to their own doctor, but, as one company representative noted, the doctor 'would probably not know what to do with these results.' In this case, the primary care provider is placed in the unfair position of explaining unclear test results with unclear utility, further muddying the waters regarding the individual's risks. More concerning would be that the DTC genetic test results could harm the patient if the primary care provider misinterpreted or misused information [4] . Although significant, the lack of proper communication and understanding is but one area of potential harm associated with DTC genetic tests for consumers. Another is privacy of healthcare information. The prospect of obtaining genetic information without having it reviewed by others, specifically healthcare professionals and medical insurance companies, may initially seem an attractive aspect of DTC testing. However, your information may in fact be far less protected in this setting than in the traditional medical model. With DTC testing the boundaries established to prevent third parties from accessing the consumers' personal data are at best illdefined, as the information and interfaces associated with DTC genetic testing are not protected to the same Health Insurance Portability and Accountability Act (HIPAA) standards that are found in the traditional healthcare setting. One specific potential route of third party access is found in the social networking outlets offered through many companies' websites. Although allowing consumers with similar genetic variants to interact in a social network could be seen as a means of enhancing education and providing support, it may also be seen by a third party as an ideal tool to advertise to a specific demographic.
Direct-to-consumer testing in the pediatric population
Although much of the debate around DTC genetic testing focuses on adult consumers, the impact of this testing will reach the pediatric age patient as well. In the United Kingdom's Human Genetic Commission's (HGC) report, 'A Common Framework of Principles for DTC genetic testing' [3] , the testing of minors was specifically addressed. The report recommended testing should be deferred until the child has attained capacity to consent unless the test is clinically indicated. However, they emphasized that such clinically indicated testing should be organized by '. . .a health professional who has responsibility for ensuring that any medical intervention or screening indicated will be arranged'. This statement is consistent with the responsibilities imparted to the healthcare provider in the traditional model of genetic testing of minors [6] . However, there is no similar standard or regulation governing the testing of minors among DTC genetic testing companies. Similarly to the lack of adequate communication between companies and consumers in regards to test results, one study found that many companies did not adequately communicate their policy regarding the processing of samples obtained from minors [8] . An additional issue that is equally important to the pediatric population and that deserves further study is the relevant psychosocial impact of DTC genetic testing on a family [6] .
As the availability of DTC genetic testing grows, pediatricians will be faced as a group with questions regarding regulation of testing, and may be faced individually with questions regarding utility of tests. These two questions are not unrelated, as utility can only be assured through appropriate regulation. In a field in which the regulation of genetic testing is outpaced by the commercialization of new testing, pediatricians and other healthcare providers should be aware of the bioethical and clinical concerns associated with DTC genetic testing.
